KU Leuven (RA Clinical Research Group, Skeletal Biology and Engineering Research Centre, Department of Development and Regeneration, KU Leuven)

Supported project of Patrick Verschueren : Rituximab is an effective drug, but it is expensive and might be accompanied by an increased infection risk. Therefore, lowering the dose might be beneficial. According to the current reimbursement criteria, patients have to wait for a flare to be retreated, which might impact their quality of life. We plan to investigate if patients benefit from a systematic retreatment combined with a gradually reduced rituximab dose compared to rituximab interval prolongation in a randomised controlled trial.